Press releaseGlobe Newswire
Theriva Biologics
TOVX · NYSE American
$0.208+$0.0033 (+1.61%)TodayMarket closed ·
Prev close $0.2047
Latest news
- Press releaseGlobe Newswire
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
- Press releaseGlobe Newswire
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- Press releaseGlobe Newswire
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseGlobe Newswire
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
- Press releaseGlobe Newswire
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsDylan Berman
Why Is Theriva Stock Gaining Monday?
- Press releaseGlobe Newswire
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
- Press releaseGlobe Newswire
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
- Press releaseGlobe Newswire
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseGlobe Newswire
$30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum
- NewsAvi Kapoor
Why Etsy Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Dow Dips Over 100 Points; US Crude Oil Inventories Surge
- NewsAvi Kapoor
Dow Surges Over 100 Points; Charles Schwab Posts Upbeat Earnings
- NewsRishabh Mishra
Stock Market Today: Nasdaq, S&P 500 Futures Gain On 3rd Day Of Government Shutdown—Rumble, Riggeti, Kodiak In Focus (UPDATED)
- NewsAvi Kapoor
Rumble, XCel Brands And 3 Stocks To Watch Heading Into Friday
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
- News
Market-Moving News for November 1st
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- NewsAvi Kapoor
Nasdaq Moves Lower; Levi Strauss Shares Slide
- NewsAvi Kapoor
Crude Oil Jumps Over 4%; US Services PMI Revised Lower
- NewsAvi Kapoor
Dow Dips Over 100 Points; US Jobless Claims Increase To 225,000
- News
Market-Moving News for October 3rd
- NewsAvi Kapoor
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.